| Full Name | Hellomed |
|---|---|
| Speciality | Family Medicine |
| Location | 2731 Plymouth Rd, Ann Arbor, Michigan |
| Authorized Official Name and Position | Joungwook Lee (CEO) |
| Authorized Official Contact | 7342492482 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Hellomed 2731 Plymouth Rd Ann Arbor MI 48105-2427 Ph: (734) 619-0777 | Hellomed 2731 Plymouth Rd Ann Arbor MI 48105-2427 Ph: (734) 619-0777 |
| NPI Number | 1164857074 |
|---|---|
| Provider Enumeration Date | 09/10/2013 |
| Last Update Date | 03/10/2024 |
| Medicare PECOS PAC ID | 5193956902 |
|---|---|
| Medicare Enrollment ID | O20140320000166 |
News Archive
One of the hopes for victory against cancer hinges on naturally-occurring proteins whose job is to make their host cell die. Since their natural role is to stop unhealthy cell proliferation, the idea is that one or more of these proteins could be harnessed to stop the growth of tumors.
The ATS congratulates the FDA on its important, but belated action, to remove flavored e-cigarette products from the U.S. market. Since e-cigarette products first emerged in the U.S., the American Thoracic Society has consistently called on FDA to aggressively regulate e-cigarettes and has repeatedly urged the FDA to ban flavored e-cigarettes from the U.S. market.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Conventional wisdom holds that malpractice lawsuits are the bane of modern medicine, with high insurance premiums driving doctors from the profession and the threat of lawsuits discouraging health-care employees from reporting and correcting medical mistakes.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164857074 | NPI | - | NPPES |
| Provider Name | Ronald F Maio |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1558444257 PECOS PAC ID: 7517871155 Enrollment ID: I20031118000090 |
News Archive
One of the hopes for victory against cancer hinges on naturally-occurring proteins whose job is to make their host cell die. Since their natural role is to stop unhealthy cell proliferation, the idea is that one or more of these proteins could be harnessed to stop the growth of tumors.
The ATS congratulates the FDA on its important, but belated action, to remove flavored e-cigarette products from the U.S. market. Since e-cigarette products first emerged in the U.S., the American Thoracic Society has consistently called on FDA to aggressively regulate e-cigarettes and has repeatedly urged the FDA to ban flavored e-cigarettes from the U.S. market.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Conventional wisdom holds that malpractice lawsuits are the bane of modern medicine, with high insurance premiums driving doctors from the profession and the threat of lawsuits discouraging health-care employees from reporting and correcting medical mistakes.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.
› Verified 1 days ago
| Provider Name | Ning J Etchill |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720246630 PECOS PAC ID: 5890856934 Enrollment ID: I20081208000069 |
News Archive
One of the hopes for victory against cancer hinges on naturally-occurring proteins whose job is to make their host cell die. Since their natural role is to stop unhealthy cell proliferation, the idea is that one or more of these proteins could be harnessed to stop the growth of tumors.
The ATS congratulates the FDA on its important, but belated action, to remove flavored e-cigarette products from the U.S. market. Since e-cigarette products first emerged in the U.S., the American Thoracic Society has consistently called on FDA to aggressively regulate e-cigarettes and has repeatedly urged the FDA to ban flavored e-cigarettes from the U.S. market.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Conventional wisdom holds that malpractice lawsuits are the bane of modern medicine, with high insurance premiums driving doctors from the profession and the threat of lawsuits discouraging health-care employees from reporting and correcting medical mistakes.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.
› Verified 1 days ago
News Archive
One of the hopes for victory against cancer hinges on naturally-occurring proteins whose job is to make their host cell die. Since their natural role is to stop unhealthy cell proliferation, the idea is that one or more of these proteins could be harnessed to stop the growth of tumors.
The ATS congratulates the FDA on its important, but belated action, to remove flavored e-cigarette products from the U.S. market. Since e-cigarette products first emerged in the U.S., the American Thoracic Society has consistently called on FDA to aggressively regulate e-cigarettes and has repeatedly urged the FDA to ban flavored e-cigarettes from the U.S. market.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Conventional wisdom holds that malpractice lawsuits are the bane of modern medicine, with high insurance premiums driving doctors from the profession and the threat of lawsuits discouraging health-care employees from reporting and correcting medical mistakes.
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.
› Verified 1 days ago
Dr. Chris Popp, Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 107 Aprill Dr Ste 5, Ann Arbor, MI 48103 Phone: 734-212-6668 Fax: 734-212-6891 | |
Regents Of The University Of Michigan Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dennis K Chernin Md Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2345 S Huron Pkwy, Ann Arbor, MI 48104 Phone: 734-973-3030 Fax: 734-973-3057 | |
South Arbor Family Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 250 W Eisenhower Pkwy, Suite 190, Ann Arbor, MI 48103 Phone: 734-707-7075 Fax: 734-707-4975 | |
Healthcare Professionals Of Ann Arbor Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3063 Oak Valley Dr, Ann Arbor, MI 48103 Phone: 734-492-0040 | |
Michigan Visiting Physician P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2900 Golfside Ste #9, Ann Arbor, MI 48108 Phone: 734-572-1666 | |
Advance Care Visiting Physicians Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3550 Burbank Dr, Ann Arbor, MI 48105 Phone: 734-451-0600 Fax: 734-451-0603 |